Arthritis drug offers children hope
Your support helps us to tell the story
From reproductive rights to climate change to Big Tech, The Independent is on the ground when the story is developing. Whether it's investigating the financials of Elon Musk's pro-Trump PAC or producing our latest documentary, 'The A Word', which shines a light on the American women fighting for reproductive rights, we know how important it is to parse out the facts from the messaging.
At such a critical moment in US history, we need reporters on the ground. Your donation allows us to keep sending journalists to speak to both sides of the story.
The Independent is trusted by Americans across the entire political spectrum. And unlike many other quality news outlets, we choose not to lock Americans out of our reporting and analysis with paywalls. We believe quality journalism should be available to everyone, paid for by those who can afford it.
Your support makes all the difference.A rheumatoid arthritis drug was relaunched in the UK today as a treatment for children whose lives are devastated by a severe form of the disease.
Tocilizumab is the first drug to be specifically licensed for systemic juvenile idiopathic arthritis (sJIA) which affects around 2,500 British youngsters.
The drug was already licensed for the treatment of adults.
Until now sJIA has mostly been treated using anti-inflammatory painkillers and steroid drugs.
Symptoms of the disease include joint pain, fever, enlargement of internal organs and a distinctive salmon-coloured skin rash.
Up to two-thirds of patients develop persistent and chronic arthritis, and half of these suffer significant disability.
Professor Patricia Woo, a rheumatology expert from Great Ormond Street Hospital for Children, said: "Systemic juvenile arthritis can be a devastating disease. It strikes often very young children, causing chronic illness, pain and disability. It is hugely encouraging to have an effective medicine now available to alleviate symptoms, control disease activity and potentially hold back the worst long-term consequences of the disease."
A Phase III trial showed that 71% of children treated with tocilizumab saw a 70% improvement after three months.
Ailsa Bosworth, chief executive of the National Rheumatoid Arthritis Society, said: "Children with sJIA and their families can now look to a future with hope."
PA
Join our commenting forum
Join thought-provoking conversations, follow other Independent readers and see their replies
Comments